Updates in the Treatment of HR+ Breast Cancer - Episode 7
Expert Perspectives in Navigating Treatment Strategies with CDK4/6 Inhibitors in HR+ Breast Cancer
A panel of experts offer perspectives in navigating treatment strategies with CDK4/6 inhibitors.
Video content above is prompted by the following:
Treatment options post progression on CDK4/6i + ET
- What is your overall perception on the class of oral SERDs? How will they continue to impact the treatment landscape?
- What are your perceptions on efficacy and safety data? What has your experience been in practice with:
- Elacestrant
- ASCO 2024 #1071: Real-world (RW) elacestrant use patterns and therapeutic outcomes.
- ASCO 2024 #1064: Elacestrant plus abemaciclib Preliminary data from ELECTRA
- ASCO 2024 #1069: Elacestrant in various combinations: Preliminary data from ELEVATE
- Bardia Cancer Res 2023: GS3-01 EMERALD phase 3 trial of elacestrant vs endocrine therapy: Updated results by duration of prior CDK4/6i in metastatic setting
- Elacestrant
Related Content:
